<DOC>
	<DOCNO>NCT03086044</DOCNO>
	<brief_summary>This open-label , pilot safety efficacy trial adult active heart lung transplantation list eligible receive organ increase risk donor evidence active prior hepatitis C infection ( HCV ) .</brief_summary>
	<brief_title>Transplanting Hepatitis C Positive Thoracic Organs</brief_title>
	<detailed_description>This open label pilot study transplant thoracic organ Hepatitis C positive donor HCV uninfected recipient Brigham Women 's Hospital . Heart lung transplant participant stratify two different study arm depend whether donor thoracic organ HCV nucleic acid amplification technology ( NAT ) positive negative . In NAT positive arm , recipient receive course direct acting antiviral ( DAA ) begin day transplant , early time point post-transplant . If donor HCV antibody ( Ab ) positive NAT negative , recipient receive close monitoring serial HCV viral load ( VL ) begin treatment DAA develop HCV viremia .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Men woman age â‰¥ 18 year Active either cardiac lung transplant wait list Willing able provide write informed consent receive organ increase risk donor know transmissible infection HIV antibody HIV NAT positive Hepatitis B surface antigen Hepatitis B NAT viral load positive Evidence cirrhosis clinically significant liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>